Trump Team Negotiates Drug Prices, Ignores Drug Company Lobbying
According to The Independent, Trump's campaign is haggling with pharmaceutical giants to offer popular weight-loss drugs like Ozempic for a ‘mere’ $149 a month. This sounds great until you remember that these same pharmaceutical companies poured $342 million into federal lobbying in 2023 alone, according to OpenSecrets.org, ensuring their pricing power remains largely unchecked on every other
drug. One wonders if these 'negotiations' are less about genuine affordability and more about a photo op for a specific demographic. While the Trump team focuses on a single class of drugs, the systemic issue remains: pharmaceutical lobbyists spend millions showering politicians from both parties to fend off any real price controls or universal healthcare models. It appears the only healthcare
'fix' in America involves a former president brokering deals that still leave patients paying over a hundred bucks a month, rather than tackling the root cause of corporate capture. How many 'savings' does it take to distract from a system designed to maximize profit margins?